CaseVuPrecipio’s Molecular Kits
Precipio’s molecular kits use proprietary mutation detection technology that is rapid, cost-effective, and easy-to-use. Our molecular kits can be run on most RT-PCR instruments to identify gene mutations and other variants at low limits of detection.
This technology enables detection of multiple genes of interest (driver mutations) for these blood cancers on a single platform, in a pre-plated assay configuration to further simplify clinical hematopathology workflows.
These molecular kits have been validated as lab developed tests at Precipio’s clinical hematopathology laboratory. They have not been approved by the FDA.
Development Of Molecular Kits
Precipio’s own clinical hematopathology laboratory developed the molecular kits panel to address the issues of turn-around time and comprehensive molecular testing. In our clinical lab, we take a panel approach to gene mutation detection to identify incidence of single mutations, mutation changes, and co-expression in a single assay. These advancements have also enabled better economics for Precipio’s clinical lab.
Typical Molecular Kit Workflow
The molecular kit workflow simplifies comprehensive analyses of driver mutations for various hematopathology diseases such as myeloproliferative neoplasms (MPN), Cytopenia, Myelodysplastic syndromes (MDS), Acute myeloid leukemia (AML), Chronic lymphocytic leukemia (CLL), and Chronic myeloid leukemia (CML). Samples are prepared using standard DNA extraction processes, followed by a simple plating step onto the pre-plated 96 well plates. These samples are then amplified and data is collected in real time, followed by simple melt curve analysis or automated quantitative analysis and interpretation for mutation detection.
For more information Contact Us